Bayer sBLA for myBETAapp, BETACONNECT accepted by FDA

Bayer's supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT Navigator has been accepted by the U.S. Food and Drug Administration.
"Mobile health technology is a growing area in healthcare communication today," Bayer Medical Director of Neurology Dr. Mark Rametta said. "The filing of myBETAapp and the BETACONNECT Navigator supports our continued commitment to meeting the needs of patients taking BETASERON to treat their relapsing forms of multiple sclerosis. We have proudly supported the MS community for more than 20 years."
The MyBETAapp was developed for patients who are taking BETASERON (interferon beta-1b) to assist them in storing the information regarding their treatment. This includes drug injections and the site of the injections. The BETACONNECT Navigator allows professionals in the health care field to look at injection history for their patients.